INT1651

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.46
First Reported 1979
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 4
Total Number 5
Disease Relevance 0.49
Pain Relevance 1.33

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

protein modification process (PLOD1) endoplasmic reticulum (PLOD1)
PLOD1 (Homo sapiens)
Pain Link Frequency Relevance Heat
agonist 28 100.00 Very High Very High Very High
narcan 14 99.08 Very High Very High Very High
Clonidine 6 98.52 Very High Very High Very High
opiate 1 98.04 Very High Very High Very High
Endogenous opioid 2 83.56 Quite High
gABA 4 75.16 Quite High
antagonist 14 71.76 Quite High
Opioid 1 25.00 Low Low
endometriosis 10 5.00 Very Low Very Low Very Low
Pain 7 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Prostate Cancer 38 93.20 High High
Cancer 7 87.44 High High
Hypersensitivity 4 27.04 Quite Low
Endometriosis (extended) 56 26.80 Quite Low
Aging 52 16.40 Low Low
Immunotherapy Of Cancer 1 9.68 Low Low
Disease 14 5.00 Very Low Very Low Very Low
Reprotox - General 3 10 5.00 Very Low Very Low Very Low
Metastasis 7 5.00 Very Low Very Low Very Low
Pain 7 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Each dose of VPA caused significant LH suppression in group I.
Positive_regulation (caused) of Negative_regulation (suppression) of LH
1) Confidence 0.46 Published 1996 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 8675571 Disease Relevance 0 Pain Relevance 0.22
The results obtained point also to a possible different pattern of LH and FSH secretion after naloxone, that is after opiate receptor blockade.
Spec (possible) Positive_regulation (point) of Spec (possible) Negative_regulation (pattern) of LH associated with narcan and opiate
2) Confidence 0.30 Published 1979 Journal Neurosci. Lett. Section Abstract Doc Link 223091 Disease Relevance 0 Pain Relevance 0.94
Conversely, increasing the dose of exogenous FSH during controlled ovarian stimulation can overcome GnRH-agonist mediated reduction of LH in many women.
Positive_regulation (overcome) of Negative_regulation (reduction) of LH associated with agonist
3) Confidence 0.13 Published 2009 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2764709 Disease Relevance 0 Pain Relevance 0.05
Conversely, increasing the dose of exogenous FSH during controlled ovarian stimulation can overcome GnRH-agonist mediated reduction of LH in many women.
Positive_regulation (mediated) of Negative_regulation (reduction) of LH associated with agonist
4) Confidence 0.13 Published 2009 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2764709 Disease Relevance 0 Pain Relevance 0.05
The pharmacological profile of subcutaneous degarelix was originally assessed in rats and monkeys.25 Single subcutaneous injections in rats produced dose-dependent reductions in LH and testosterone levels and the duration of LH suppression was found to increase with dose.
Positive_regulation (increase) of Negative_regulation (reductions) of LH
5) Confidence 0.07 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004563 Disease Relevance 0.49 Pain Relevance 0.07

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox